術後感染症に対するSulbactam/CefbPerazoneとCeftizoximeの薬効比較試験

小池 明彦; 正岡 昭; AKIRA MISHIMA; AKIRA MIZUNO; 鈴木 宏志; 由良 二郎; KAZUAKI MATSUMOTO; 入山 圭二; 加藤 健一; 松本 好市; 竹重 言人; 片岡 誠; 安藤 正英; 藤岡 正樹; 堀沢 増雅; 河野 恵; 品川 長夫; 小川 暢也; 石川 周; 伊藤 忠夫; 近藤 達平

doi:10.11553/antibiotics1968b.38.643

CLINICAL ASSESSMENT OF SULBACTAM/CEFOPERAZONE IN COMPARISON WITH CEFTIZOXIME IN PATIENTS WITH POSTOPERATIVE INFECTIONS BY WELL CONTROLLED METHOD

AKIHIKO KOIKE, AKIRA MASAOKA, AKIRA MISHIMA, AKIRA MIZUNO, HIROSHI SUZUKI, JIRO YURA, KAZUAKI MATSUMOTO, KEIJI IRIYAMA, KENICHI KATO, KOICHI MATSUMOTO, KOTOHITO TAKESHIGE, MAKOTO KATAOKA, MASAHIDE ANDO, MASAKI FUJIOKA, MASUMASA HORISAWA, MEGUMI KOHNO, NAGAO SHINAGAWA, NOBUYA OGAWA, SHU ISHIKAWA, TADAO ITO, TATSUHEI KONDO

Author information

AKIHIKO KOIKE
The Second Department of Surgery, Aichi Medicine College
AKIRA MASAOKA
The Second Department of Surgery, Nagoya City University, Medical School
AKIRA MISHIMA
The First Department of Surgery, Nagoya City University, Medical School
AKIRA MIZUNO
The First Department of Surgery, Nagoya City University, Medical School
HIROSHI SUZUKI
The Second Department of Surgery, School of Medicine, Mie University
JIRO YURA
The First Department of Surgery, Nagoya City University, Medical School
KAZUAKI MATSUMOTO
The First Department of Surgery, Nagoya City University, Medical School
KEIJI IRIYAMA
The Second Department of Surgery, School of Medicine, Mie University
KENICHI KATO
The Second Department of Surgery, Aichi Medicine College
KOICHI MATSUMOTO
The Second Department of Surgery, School of Medicine, Mie University
KOTOHITO TAKESHIGE
The Second Department of Surgery, Aichi Medicine College
MAKOTO KATAOKA
The Second Department of Surgery, Nagoya City University, Medical School
MASAHIDE ANDO
The First Department of Surgery, Nagoya City University, Medical School
MASAKI FUJIOKA
The Second Department of Surgery, School of Medicine, Mie University
MASUMASA HORISAWA
The Second Department of Surgery, School of Medicine, Nagoya University
MEGUMI KOHNO
The Second Department of Microbiology, Tokyo Pharmacy College
NAGAO SHINAGAWA
The First Department of Surgery, Nagoya City University, Medical School
NOBUYA OGAWA
Department of Pharmacology, School of Medicine, Ehime University
SHU ISHIKAWA
The First Department of Surgery, Nagoya City University, Medical School
TADAO ITO
Department of Surgery, Tajimi City Hospital
TATSUHEI KONDO
The Second Department of Surgery, School of Medicine, Nagoya University

JOURNAL FREE ACCESS

1985 Volume 38 Issue 3 Pages 643-670

DOI https://doi.org/10.11553/antibiotics1968b.38.643

Details

Abstract

The clinical effectiveness in postoperative infections of sulbactam/cefoperazone (SBT/CPZ,(SBT 0.5g+CPZ 0.5g)×2/day) was compared to that of ceftizoxime (CZX, 1.0g×2/day) by a well controlled comparative study, to have the following results.
1. The overall effectiveness rate of SBT/CPZ and CZX as judged by Judgement Committee was 84.0% (63/75) and 80.6% (50/62), respectively, and the effectiveness of SBT/CPZ and CZX as assessed by the attending surgeons was 84.0% (63/75) and 71.0% (44/62), respectively. No significant difference was noted in both assessments. In a total of 36 SBT/CPZ-treated patients with intraabdominal infections, the clinical efficacy was judged by attending surgeons to be excellent in 13 patients (36.1%), and to be excellent or good in 31 (86.1%). In the 30 CZX treated patients, it was judged to be excellent in 6 patients (20.0%), and to be excellent or good in 19 (63.3%). These results presented a significant difference (P<0.05, U-test) between the 2 drug groups.
2. The final global improvement ratio judged by attending surgeons was 85.3% (64/75) for SBT/CPZ, and 79.0% (49/62) for CZX with no significant difference. In assessment of time-course improvement, the improvement ratio of SBT/CPZ on day 4 was significantly better than that of CZX (P<0.05, U-test).
3. The usefulness rate of SBT/CPZ and CZX was 84.0% (63/75) and 73.0% (46/63), respectively. There was no significant difference between the 2 drug groups.
4. To assess the bacteriological efficacy, the eradication rate of SBT/CPZ was compared to that of CZX. There was no significant difference between 85.7% (36/42) for SBT/CPZ and 73.5% (25/34) for CZX.
5. After SBT/CPZ administration, 2 patients (2.5%) complained of side effects. In the clinical labolatory tests, abnormality related to SBT/CPZ medication was observed in 6 patients (7.5%), and that related to CZX, in 5 patients (6.4%). As to the types of side effects and frequency, no significant difference was observed between SBT/CPZ and CZX.
It is concluded from the above assessments that SBT/CPZ is a useful drug in the treatment of post-operative infections.

Corresponding author

Register with J-STAGE for free!